In Search Of Goodwill, Several Pharmas Commit To New Corporate ‘Statement Of Purpose’

20 Aug 2019

The updated business principles may give pharma companies leverage, or at least talking points, as they continue to engage with the Trump administration on policies like the International Pricing Index and with US lawmakers on drug pricing legislation. J&J's Gorsky heads governing committee of multi-industry business group that revised its principles.

Goodwill — Will Pharma's Renewed Focus On Customers Extend To Pricing?

The leaders of the half dozen pharmaceutical manufacturers who are members of the US-based Business Roundtable signed on to the organization’s updated principles on the “role of a corporation,” announced 19 August.

The principles embrace a commitment to serving the concerns of consumers, employees, suppliers and communities over shareholders

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pharma Left Hanging After US/UK Trade Pact

09 May 2025

• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Novartis Doubles Down On Push For Higher Drug Prices In Europe

01 May 2025

• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

29 Apr 2025

• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Soriot Cautions Europe Amid More US Expansion

29 Apr 2025

• By Kevin Grogan

The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into Phase III For IPF

12 May 2025

• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.